Inspyr Therapeutics, Inc. is a Los Angeles-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. Inspyr's lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).
Sign up for E-mail Alerts
Be the first to receive breaking newsSign Up Today